Biotech sheds staff, sells drug to sharpen focus (Hep C)

Biotech sheds staff, sells drug to sharpen focus
San Francisco Business Times - has agreed to sell rights to its chronic hepatitis C drug Infergen for up to $135.5 million to Valeant Pharmaceuticals

HIV-HCV Coinfected Patients Receive Treatment for Chronic Hepatitis C Less Frequently Than HCV Monoinfected
HIV and Hepatitis.com - By Marina Nunez, MD "End-stage liver disease has become a leading cause of morbidity and mortality in HIV-infected patients since the introduction of HAART.

FDA gives Fast Track status to Vertex's Hepatitis C treatment
Mass High Tech - the FDA granted the Fast Track designation because chronic hepatitis C virus infection is a serious and life-threatening

Idenix Pharmaceuticals, Inc. (IDIX) Release: Partial 24-Week Data Demonstrate Valopicitabine (NM283) Combined
BioSpace - pegylated interferon in treatment-refractory patients with chronic hepatitis C. These 24-week data demonstrate continued